Covishield maker AstraZeneca, SII, govt all responsible for my daughter's death: Father to file case along with 8 parents
In a heartbreaking turn of events, the parents of Karunya, who tragically passed away in 2021 after allegedly receiving the Covishield vaccine, are seeking legal recourse. Her grieving father, Venugopalan Govindan, blames multiple parties for his daughter's death and is determined to hold them accountable. (Source: The Economic Times)
Source: The Economic Times - May 3, 2024 Category: Consumer Health News Source Type: news
Govt calls meet to discuss measures to bring gloves under quality control
Union government's high-level meeting aims to address the issue of substandard glove imports from Southeast Asia, focusing on implementing quality control orders for surgical gloves to ensure better standards in the domestic market. (Source: The Economic Times)
Source: The Economic Times - May 2, 2024 Category: Consumer Health News Source Type: news
Quadria cap picks up minority stake in NephroPlus
NephroPlus, India's largest dialysis chain, has secured $103 million (₹860 crore) in a Series F funding round led by Quadria Capital. This funding, a mix of fresh capital and a secondary sale, aims to drive expansion plans within India and targeted markets overseas. The primary component of the funding is ₹100 crore. Quadria Capital will become a minority shareholder, valuing NephroPlus at over ₹2,000 crore. Existing investors like Bessemer Venture Partners, International Finance Corporation, and IIFL also participated in the funding round, reducing their stakes. (Source: The Economic Times)
Source: The Economic Times - May 2, 2024 Category: Consumer Health News Source Type: news
Took AstraZeneca's Covishield? Should I be worried? What are the risky side effects I shouldn't ignore? Here are all the answers
AstraZeneca's admission of Covishield's potential link to Thrombosis with Thrombocytopenia Syndrome (TTS) has stirred concerns. Despite its rarity, social media debates over vaccine safety persist. Covishield, similar to AstraZeneca's, faces scrutiny, though TTS isn't exclusive to them. Here are all the answers about your doubts related to the recent controversy over AstraZeneca's Covishield. (Source: The Economic Times)
Source: The Economic Times - May 2, 2024 Category: Consumer Health News Source Type: news
Amid Covishield row, what WHO says on side-effects from Covid vaccine? Should you be worried?
Recent revelations by pharmaceutical company AstraZeneca have brought Covid vaccines back into the spotlight, with acknowledgment that its AstraZeneca-Oxford vaccine can, in very rare instances, lead to Thrombosis Thrombocytopenia Syndrome (TTS)," a condition involving the formation of blood clots in blood vessels. Despite these rare occurrences, the pharmaceutical firm maintains that extensive clinical trial data and real-world evidence consistently support the safety and effectiveness of the vaccine. (Source: The Economic Times)
Source: The Economic Times - May 1, 2024 Category: Consumer Health News Source Type: news
What WHO says on side-effects from Covid vaccine? Should you be worried?
Recent revelations by pharmaceutical company AstraZeneca have brought Covid vaccines back into the spotlight, with acknowledgment that its AstraZeneca-Oxford vaccine can, in very rare instances, lead to Thrombosis Thrombocytopenia Syndrome (TTS)," a condition involving the formation of blood clots in blood vessels. Despite these rare occurrences, the pharmaceutical firm maintains that extensive clinical trial data and real-world evidence consistently support the safety and effectiveness of the vaccine. (Source: The Economic Times)
Source: The Economic Times - May 1, 2024 Category: Consumer Health News Source Type: news
Lilavati trustee alleges Rs 500 crore scam by kin
Prashant Mehta, a trustee of Lilavati Hospital & Research Centre in Mumbai, accused former trustees of misappropriating ₹500 crore in trust funds. Allegations include payments for private disputes, bogus donations, and advances to real estate firms. Prashant named his late uncle Vijay Mehta, cousin Niket Mehta, and aunt Sushila Mehta in the accusations. (Source: The Economic Times)
Source: The Economic Times - April 30, 2024 Category: Consumer Health News Source Type: news
Covishield row: 'Very rare chances…', ex-AIIMS doctor explains severe side-effects of covid vaccine
(Source: The Economic Times)
Source: The Economic Times - April 30, 2024 Category: Consumer Health News Source Type: news
Manipal Hospitals scouts for aggressive growth: MD
Manipal Hospitals, India's largest hospital chain with 10,500 beds, considers its current figure of beds "insignificant" in the country's context and is actively seeking acquisitions. They recently signed an agreement to acquire an 87% stake in Kolkata-based Medica Synergie for about Rs 1,400 crore, aiming to become the largest hospital chain in India. Manipal plans to expand in the eastern region and other locations like Kerala, Vizag, and Hyderabad. (Source: The Economic Times)
Source: The Economic Times - April 30, 2024 Category: Consumer Health News Source Type: news
AstraZeneca Covishield causes rare disease: What is TTS? Symptoms and how it affects you
Covishield blood clot disease: Thrombosis Thrombocytopenia Syndrome (TTS) refers to the clot in blood vessels, and it occurs in very rare cases, following the use of certain types of vaccines (Source: The Economic Times)
Source: The Economic Times - April 30, 2024 Category: Consumer Health News Source Type: news
Covishield Side Effects: What's TTS syndrome, symptoms, and danger signs you shouldn't ignore
Covishield TTS: AstraZeneca has acknowledged the potential TTS side effects from its COVID-19 vaccine Covishield, used widely in India. TTS, Thrombosis with Thrombocytopenia Syndrome, is rare but serious, marked by blood clots and low platelet levels. Symptoms include headaches, blurred vision, and chest pain. Dr. Jayadevan emphasizes awareness, stressing early treatment for effective management. AstraZeneca's admission follows reports of TTS linked to adenovirus vector vaccines. (Source: The Economic Times)
Source: The Economic Times - April 30, 2024 Category: Consumer Health News Source Type: news
AstraZeneca acknowledges its covid vaccine, Covishield, can lead to rare blood clot side effects; Here's what we know
Covishield Covid Vaccine: The Covishield COVID-19 vaccine, developed by AstraZeneca in partnership with the University of Oxford, has been acknowledged for its potential to induce a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). This acknowledgment coincides with a legal case alleging severe adverse effects, including fatalities, linked to the vaccine. Kate, the spouse of one affected individual, calls for an apology and just compensation after a three-year ordeal. (Source: The Economic Times)
Source: The Economic Times - April 29, 2024 Category: Consumer Health News Source Type: news
AstraZeneca acknowledges its covid vaccine can lead to rare blood clot side effects; Here's what we know
AstraZeneca, in collaboration with the University of Oxford, admits its Covid-19 vaccine can cause a rare side effect, Thrombosis with Thrombocytopenia Syndrome (TTS). The admission comes amidst a lawsuit alleging severe harm and deaths caused by the vaccine. Kate, wife of a victim, demands an apology and fair compensation after a three-year struggle. The lawsuit, involving fifty-one cases, seeks around £100 million in compensation. (Source: The Economic Times)
Source: The Economic Times - April 29, 2024 Category: Consumer Health News Source Type: news
AstraZeneca acknowledges covid vaccine can lead to rare side effect TSS in court; Here's what we know
AstraZeneca, in collaboration with the University of Oxford, admits its Covid-19 vaccine can cause a rare side effect, Thrombosis with Thrombocytopenia Syndrome (TTS). The admission comes amidst a lawsuit alleging severe harm and deaths caused by the vaccine. Kate, wife of a victim, demands an apology and fair compensation after a three-year struggle. The lawsuit, involving fifty-one cases, seeks around £100 million in compensation. (Source: The Economic Times)
Source: The Economic Times - April 29, 2024 Category: Consumer Health News Source Type: news
Manipal Hospitals to acquire Kolkata's Medica Synergie
Manipal Hospitals has acquired an 87% stake in Kolkata-based Medica Synergie, a subsidiary of Singapore's Temasek Holdings. The deal, valued at Rs1200 crore, is part of Manipal Hospitals' strategy to expand its presence in Eastern India. The acquisition comes after Sheares Health, the healthcare platform owned by Singapore's Temasek Holdings, acquired an additional 41% stake from existing investors and the promoter family for Rs16,500 crore. (Source: The Economic Times)
Source: The Economic Times - April 29, 2024 Category: Consumer Health News Source Type: news
